1. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Issue 7 (July 2021) Authors: Flume, Patrick A; Biner, Reta Fischer; Downey, Damian G; Brown, Cynthia; Jain, Manu; Fischer, Rainald; De Boeck, Kris; Sawicki, Gregory S; Chang, Philip; Paz-Diaz, Hildegarde; Rubin, Jaime L; Yang, Yoojung; Hu, Xingdi; Pasta, David J; Millar, Stefanie J; Campbell, Daniel; Wang, Xin; Ahluwalia, Ne... Journal: Lancet Issue: Volume 9:Issue 7(2021) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis. Issue 3 (9th March 2017) Authors: White, Helen; Shaw, Nicola; Denman, Sarah; Pollard, Kim; Wynne, Sarah; Peckham, Daniel Gavin Journal: European respiratory journal Issue: Volume 49:Issue 3(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗